SCHEMBL18292682

SCHEMBL18292682

COc1ccc(-c2[nH]c(-c3cccc(O)c3)nc2-c2ccccc2)cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.70
NOX1 Q9Y5S8 2/20 0.70
SMPD3 Q9NY59 6/20 0.66
MPO P05164 1/20 0.64
MAPT P10636 8/20 0.64
TDP1 Q9NUW8 2/20 0.64
KDM4E B2RXH2 2/20 0.64
ALDH1A1 P00352 2/20 0.64
HPGD P15428 2/20 0.64
LMNA P02545 1/20 0.64
HTT P42858 1/20 0.64
TP53 P04637 4/20 0.63
THRB P10828 1/20 0.63
MAPK13 O15264 1/20 0.56
RAF1 P04049 1/20 0.56
BRAF P15056 1/20 0.56
MAPK12 P53778 1/20 0.56
MAPK11 Q15759 1/20 0.56
MAPK14 Q16539 1/20 0.56
BRDT Q58F21 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18292680 0.88 NOX1 (0.78) PTPN1NOX1SMPD3MPOMAPT
SCHEMBL18292681 0.88 SMPD3 (0.85) NOX1SMPD3MPOMAPTTDP1
SCHEMBL14335897 0.85 PTPN1 (0.69) PTPN1NOX1SMPD3MPOMAPT
SCHEMBL18292684 0.84 MAPT (0.69) NOX1SMPD3MPOMAPTTDP1
SCHEMBL12561702 0.83 PTPN1 (1.00) PTPN1NOX1SMPD3MAPTTP53
SCHEMBL1068914 0.83 PTPN1 (0.94) PTPN1NOX1SMPD3MAPTTP53
SCHEMBL6465030 0.83 MAPK13 (0.71) NOX1SMPD3MPOMAPTTDP1
SCHEMBL15075623 0.83 MAPK13 (0.71) NOX1SMPD3MPOMAPTTDP1
SCHEMBL8088592 0.83 NOX1 (0.81) PTPN1NOX1SMPD3MPOMAPT
SCHEMBL18292686 0.82 MAPT (0.73) NOX1SMPD3MPOMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D PTPN1 1275/4885NOX1 3444/4885SMPD3 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.